Metsera (NASDAQ:MTSR) Now Covered by Evercore ISI

Research analysts at Evercore ISI assumed coverage on shares of Metsera (NASDAQ:MTSR) in a research note issued on Tuesday,Benzinga reports. The firm set an “outperform” rating on the stock.

Metsera Price Performance

Shares of MTSR stock opened at $29.81 on Tuesday. Metsera has a 12-month low of $25.06 and a 12-month high of $32.81.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.